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Background. Patients with inﬂammatory bowel disease (IBD) are at high risk of developing osteoporosis. Our objective was
to determine the usefulness of IBD guidelines in identifying patients at risk for developing osteoporosis. Methods.W eu t i l i z e d
institutional repository to identify patients seen in IBD center and extracted data on demographics, disease history, conventional,
andnonconventionalriskfactorsforosteoporosisandDualEnergyX-rayAbsorptiometry(DXA)ﬁndings.Results.59%ofpatients
(1004/1703) in our IBD cohort had at least one risk factor for osteoporosis screening. DXA was documented in 263 patients with
indication of screening (provider adherence, 26.2%), and of these, 196 patients had DXA completed (“at-risk” group). Ninety-ﬁve
patientsnotmeetingguidelines-based riskfactorsalsohadDXAcompleted (“notat-risk”group).139(70.9%)patientsin“at-risk”
group had low BMD, while 51 (53.7%) of “not-at-risk” patients had low BMD. Majority of the patients with osteoporosis (83.3%)
missed by the current guidelines had low BMI. Multivariate logistic regression analysis showed that low BMI was the strongest
risk factor for osteoporosis (OR 3.07; 95% CI, 1.47–6.42; P = 0.003). Conclusions. Provider adherence to current guidelines is
suboptimal. Low BMI can identify majority of the patients with osteoporosis that are missed by current guidelines.
1.Introduction
Inﬂammatory bowel disease (IBD) is a common disorder,
aﬀecting about 1.4 million people in the United States and
2.2 million people in Europe. The incidence of fractures
among patients with IBD is reported to be 40% higher than
in the general population [1]. Osteoporosis and osteopenia,
characterized by low bone mineral density (BMD), are
increasingly recognized as common extraintestinal features
of IBD that increase fracture risk. Estimates vary based on
study populations and location, but in general prevalence
of osteopenia and osteoporosis in patients with IBD ranges
from 22%–77% and 17%–41% for osteopenia and osteo-
porosis, respectively [2–4]. The pathogenesis of low BMD in
IBD is complex and considered to be multifactorial. Risk fac-
torsforthedevelopmentoflowBMDincludethegeneralrisk
factors for osteoporosis such as age, smoking as well as IBD-
speciﬁc risk factors such as corticosteroid use, malnutrition,
small bowel resection, vitamin D (25-hydroxyvitamin D [25-
OHD]) deﬁciency, and proinﬂammatory cytokines [5, 6].
Recognizing the increased risk for fractures in patients with
low BMD, American College of Gastroenterology (ACG) and
American Gastroenterology Association (AGA) guidelines
recommend screening IBD patients with Dual Energy X-ray
Absorptiometry (DXA) if they have one of the following risk
factors: postmenopausal state, ongoing corticosteroid treat-
ment, cumulative prior use of corticosteroids exceeding 3
months, history of low-trauma fractures, or age over 60 [7–
9].
There is limited literature determining the utility of these
guidelines in identifying the patients at risk for low BMD.
In a study of 100 consecutive patients, Kornbluth et al.2 The Scientiﬁc World Journal
showed that among patients who met the AGA criteria for
initial DXA screening, osteoporosis was found in 12% and
osteopenia in another 44% [10]. While this study showed
the positive predictive value of AGA guidelines, it did not
speciﬁcally assess the negative predictive value of screening
criteria proposed by guidelines. In other words, if a patient
does not meet the screening guidelines, can he or she still be
at risk for low BMD and fractures? This question is especially
relevant since these guidelines published many years ago do
not take into account clinical risk factors such as low body
mass index (BMI) that has been strongly associated with
low BMD and increased fracture risk in multiple studies in
general population. In fact, the WHO fracture risk predictor
model (FRAX) based on data derived from nine cohorts
from Europe, North America, Asia, and Australia includes
low BMIasanimportant clinical predictor to predict10-year
probability of fracture [11]. The purpose of this study was to
evaluate the utility of osteoporosis screening guidelines in a
large outpatient IBD practice, assess provider adherence, and
determinetheimpactofnonconventionalriskfactorssuchas
low BMI that are not included in current guidelines.
2. Methods
We utilized institutional clinical data repository to identify
patients >18 years of age who were seen at least twice
in our tertiary care IBD practice and had a diagnosis of
Crohn’s disease (CD, ICD-9-CM code 555.xx) or ulcerative
colitis (UC, ICD-9-CM code 556.xx). We then extracted
demographic, laboratory, and DXA information on study
patients and reviewed patients’ charts for clinical informa-
tion and data related to conventional (age, steroid use, and
postmenopausal status) and nonconventional risk factors
(low body mass index, BMI <21kg/m2, total or subtotal
colectomy) for low BMD. Any patient with cumulative oral
steroid prescriptions lasting greater than 3 months was
considered to have “steroid use.” Patients who were found
to have unconﬁrmed UC, CD, or indeterminate colitis in
manual review of clinical notes were excluded from the
study. World Health Organization (WHO) criteria for low
BMD were applied for this analysis [11]. A T score of −1
represents a BMD measurement 1 SD below the mean, and
each SD decline in T score is associated with an approximate
doubling of relative risk of fracture [12]. T scores between 1
and 2.5 SDs below the average for the reference population
were classiﬁed as osteopenia. Measurements 2.5 SDs or more
below the young adult mean were classiﬁed as osteoporosis.
All patients who underwent DXA screening and had
BMDmeasurementsavailabletouswereincludedforfurther
analysis. Diﬀerences between the demographics, clinical
characteristics, and risk factors for patients with normal
and low BMD were determined by Fisher’s exact test for
categorical variables and Student’s t-test or Mann-Whitney
U-testforcontinuousvariables.Variablesthatappearedtobe
imbalanced between the two groups were included into the
multivariable models. BMD was modeled as T score above
or below the cutoﬀ value for osteopenia (i.e., 1 SDs below the
young adult mean value). The odds ratio (OR) of low BMD
was then estimated in a multivariable logistic regression
model. The level of signiﬁcance was set at 0.05 and analyses
were done using SPSS Statistical Software Package (version
16.0, Chicago, IL). The study was approved by Cleveland
Clinic Institutional Review Board.
3. Results
3.1. Demographic and Clinical Baseline Data. A total of 1703
IBD patients were seen in our IBD center for more than
one visit from 2003–2008. Flowchart in Figure 1 shows the
categorization of patients in the study. Out of these 1703
patients, 1004 (59%) had at least one indication for DXA
scanning as per current guidelines. DXA was ordered or
mentioned in electronic health record (EHR) system for 263
out of these 1004 patients (provider adherence 26.2%). Of
these 263, 220 (83.6%) patients completed the scan. DXA
scan was also ordered in 121 patients who did not have
any conventional risk factors (“not at risk” group); of these
99 patients completed the scan. Hence, a total of 319 IBD
patients completed at least one DXA scan.
From the 319 patients on who had DXA completed,
28 patients with DXA done outside our health system did
not have DXA reports available for conﬁrmation and were
excluded from further analysis. Table 1 shows the demo-
graphic characteristics, risk factors, and outcomes of 291
remaining IBD patients, categorized into “at risk” group
(those to who met the guidelines, n = 196) and “not at
risk” group (n = 95). 139 (70.9%) of patients in “at-risk”
group had low BMD (osteoporosis, 45 (23.0%); osteopenia
94 (47.9%)) while 51 (53.7%) of “not-at-risk” patients
had low BMD (osteoporosis, 12 (12.6%), osteopenia 39
(41.1%)). As expected, “not-at-risk” group was more likely
to have patients with normal BMD than patients in “at-risk”
group (41.1% versus 48%, 0.008). Overall, 42/57 (73.0%) of
patients with osteoporosis and 51/133 (38.3%) with osteope-
nia were documented to be on one of the antiresorptive
agents. Bisphosphonates alone or in combination were most
commonly used antiresorptive agents in both osteoporosis
(41/57, 71.9%) and osteopenia (50/133, 37.6%).
Multivariate logistic regression analysis showed that low
BMIwasthestrongestindependentriskfactorforosteoporo-
sis (OR 3.07, 95% CI 1.47–6.42) (Table 2). Age (OR 1.02,
95% CI 1.00–1.05) and femalegender(OR2.09; CI 0.99–4.4)
were also associated with osteoporosis; however, the relation
was not as strong as with low BMI. Disease condition CD
or UC was not a predictor of osteoporosis. Subset analysis
showedthatcigaretteusehadavariableeﬀectonBMDinCD
and UC patients. In CD, there was no association of BMD
with cigarette smoking (OR 1.1, 95% CI 0.55–2.19). How-
ever, in UC, cigarette smoking was associated with decrease
in risk of developing low BMD (OR 0.27, 95% CI 0.1–0.7).
Figures 2(a) and 2(b) show a schematic representation of
incremental yield of adding low BMI to current guidelines in
detecting patients with low BMD in our cohort. As seen in
the ﬁgures, low BMI alone can yield about the same utility
as the current screening guidelines. More speciﬁcally, low
BMI identiﬁed 10 out of 12 (83.3%) osteoporotic patientsThe Scientiﬁc World Journal 3
1703 patients
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Figure 1: Flow chart of the initial Inﬂammatory Bowel Disease (IBD) cohort and the ﬁnal list of patients who did not meet (“not at risk”)
and met (“at-risk” group) the indications for osteoporosis screening per the guidelines.
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Figure 2: (a) Shows the impact of including low body mass index (BMI) to current guidelines in detecting additional cases of osteoporosis.
(b) Shows the impact of including low body mass index (BMI) to current guidelines in detecting additional cases of osteopenia.4 The Scientiﬁc World Journal
Table 1: Characteristics of patients in the “not at-risk” and “at-risk” groups deﬁned by absence or presence of fulﬁlling current screening
guidelines.
Characteristic Not at-risk
(n = 95)
At-risk
(n = 196) P value
Demographics
Age ± SD (years) 43.6 ±10.94 8 .3 ±16.20 . 0 1
Female gender (%) 69.5 58.2 0.15
Ethnicity (%) 0.43
White 90.5 86.2
African American 5.3 10.3
Other 4.3 3.5
Risk factors (%)
Crohn’s disease (%) 63.2 63.8 1.00
Smoking (%) 0.17
Current 24.5 14.4
Past 24.5 39.7
Colectomy (%) 4.2 8.3 0.26
Partial 30.9 35.3
Complete 26.6 18.2
Low body mass index (<21kg/m2) (%) 47.4 48.1 1.00
Outcome (%) 0.008
Normal Bone mineral density 46.3 29.1
Osteopenia 41.1 48.0 0.52
Osteoporosis 12.6 23.0 0.52
Data reported in percentage (%) for categorical variables, mean ± standard deviation (SD) for continuous variables.
Table 2: Results of the multivariate logistic regression in our IBD
cohort with osteoporosis as the primary outcome.
Variable Odds ratio 95% CI Signiﬁcance (P)
Low BMI 3.07 1.47–6.42 0.003
Age 1.02 1.00–1.05 0.05
Female Gender 2.09 0.99–4.4 0.05
Steroid use 1.64 0.79–3.42 0.18
Colectomy 1.7 0.84–3.43 0.14
and 17 out of 39 (43.6%) osteopenic patients missed by
the current guidelines. Furthermore, inclusion of low BMI
to current guidelines can lead to identiﬁcation of majority
of osteoporosis (53/57, 96.5%) and osteopenic patients
(111/133, 83.5%).
4. Discussion
The primary objective of this study was to evaluate the utility
of osteoporosis screening guidelines in a large outpatient
IBD practice and determine the impact of nonconventional
r i s kf a c t o r ss u c ha sl o wB M It h a ta r en o ti n c l u d e di n
current guidelines. Our study conﬁrmed ﬁndings from prior
study by Kornbluth et al. about the utility of osteoporosis
screening guidelines in IBD population [10]. More than
two-thirds of patients (70.9%) in “at risk” group identiﬁed
by guidelines had low BMD and majority of these patients
were started on antiresorptive agents to address low BMD.
Age and steroid use were associated with risk of having low
BMD. However, about half (53.7%) of patients without the
conventionalriskfactor(“notat-risk”group)hadosteopenia
or osteoporosis in our study. This shows that negative
predictive value of guidelines-based screening approach is
not good and a substantial numbers of patients at risk
can go undetected if only conventional risk factors are
considered. Our multivariate analysis showed that low BMI
was the strongest independent risk factor for osteoporosis,
with low BMI patients more than three times as likely to
have osteoporosis irrespective of the screening guidelines.
Addition to low BMI to current guidelines will result in
screening of majority of patients found to have low BMD in
our cohort.
Our study results are consistent with emerging literature
showing low BMI as a strong risk factor for low BMD in both
IBD and non-IBD population. In fact, low BMI is included
in WHO fracture risk predictor model (FRAX) that is based
on data derived from nine international cohorts and vali-
dated in may more independent cohorts with a widespread
geographic distribution [13]. In 2006, Bartram et al. [14],
reported independent association between low BMI and
osteoporosis among CD patients in United Kingdom. In a
subsequent study in Scottish population, Noble et al. showed
alinearcorrelationbetweenTscoreatthevertebralspineand
BMI in patients with CD [15]. After adjusting for smoking,
steroid use, Montreal location, and behavior, BMI remainedThe Scientiﬁc World Journal 5
robust predictor of osteoporosis in CD patients (OR 5.83,
CI 1.31–25.94, P = 0.021). Our study supports the British
Society of Gastroenterology guidelines that low BMI is a
strong risk factor for low BMD in not only CD but also in
UC patients [16].
Our study also highlights the continued problem of sub-
optimal physician adherence to osteoporosis screening and
management guidelines in IBD patients published in 2003.
In 2005, Reddy et al. found that 78% of the IBD patients on
chronic steroid therapy did not undergo any BMD scanning
or receive any pharmacological therapy for prevention of
metabolic bone disease [17]. Wagnon et al. reported that
majority of clinicians (57%) did not use the guidelines in
managementoftheirIBDpatientsevenin2009[18].Greatest
barrier, according to their study, was the perception among
cliniciansthatIBD,andnotosteoporosis,shouldbethefocus
of the visit. Also, gastroenterologists are not traditionally
trained in evaluation and management of metabolic bone
disease. Kane and Reddy showed that even after reading the
guidelines, only 25% of gastroenterologists felt comfortable
managing osteoporosis [19]. Unfortunately, as shown in our
study, adherence to guidelines alone will not be suﬃcient
in decreasing fracture risk in our IBD population since
the guidelines themselves may miss many patients at risk.
Hence, eﬀorts need to be made not only in better adoption
of guidelines but also in revising the current guidelines to
include nonconventional risk factors such as BMI in assess-
ment of fracture risk. Fortunately, BMI is easy to understand
and measure. Majority of electronic health records available
today calculate BMI automatically, making it easy to be
incorporated into decision making tools such as FRAX.
Several potential limitations concerning our study ﬁnd-
ings need to be addressed. First, there may be a selection bias
with respect to the patients who underwent DXA screening.
Our IBD cohort included a large number of patients who
were referred to our tertiary center for management of IBD
and its complications. Therefore, they are more likely to have
more severe disease and a greater risk for osteoporosis. Fu-
rthermore, it is possible that physicians may have chosen to
orderDXAbasedondiseaseseverityeveniftheydidnotmeet
criteria for age, steroid use, postmenopausal state, or history
oflow-traumafractures.Thismayhaveaccountedforslightly
higherprevalenceoflowBMDseeninourstudyascompared
to other studies in IBD population [10, 19]. Increased num-
berofreferralpopulationmayalsoexplain,inpart,lownum-
ber of DXA screenings ordered in our electronic health re-
cords. It is possible that physicians discussed DXA screenings
and patients underwent DXA at a local facility, outside our
health system. We tried to capture outside hospital DXA
results by extracting this information from clinical notes
documented in our EHR but cannot be sure that all outside
hospital DXA results were included in clinical notes. Thirdly,
BMD is just one of the many factors that contribute to
fracturerisk[12,20,21].Studieshaveshownthatalargepart
of variance in fracture risk is not explained by BMD alone,
and low BMI may predict fracture risk independent of BMD
too [19, 22]. Hence, fracture risk assessment tools like FRAX
that include low BMI as risk factor with or without DXA
are increasingly advocated in general population to make
treatment decisions in patients at risk for fractures [23]. Fu-
ture studies looking at applicability of FRAX scores in IBD
population and determining the beneﬁts of nutritional
intervention in IBD patients with low BMI on bone density
and fracture risk will be of great interest.
Inconclusion,thisstudyrevealsthatcurrentosteoporosis
screeningguidelinesinIBDpopulationcanmissasubstantial
proportion of patients at risk for fractures. Low BMI is an
independent and strong risk factor for osteoporosis in both
UC and CD patients and should be incorporated in revised
guidelines. Future studies should look at applicability of
FRAX scores in IBD population and make treatment de-
cisions based on future fracture risk rather than BMD values
alone.
What is current knowledge
(i) Patients with inﬂammatory bowel disease (IBD) are
at increase risk for osteoporosis and osteopenia.
(ii) Current guidelines recommend screening IBD pa-
tients with Dual Energy X-ray Absorptiometry
(DXA) if they have one of the following risk factors:
postmenopausal state, ongoing corticosteroid treat-
ment, cumulative prior use of corticosteroids exceed-
ing 3 months, history of low trauma fractures, or age
over 60.
What is new here
(i) Guidelines fail to identify many patients who were
found to have osteoporosis or osteopenia.
(ii) Low body mass index (BMI) is a strong predictor of
lowbonemineraldensityandinclusionoflowBMIto
current guidelines will help identify majority of IBD
patients at risk for osteoporosis or osteopenia.
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